Adjuvant immunotherapy for cancer: the next step
Mené sur 951 patients atteints d'un mélanome de stade III, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans récidive, et la toxicité de l'ipilimumab en traitement adjuvant après résection complète de la tumeur
Immunotherapy is firmly entrenched in the management of patients with advanced melanoma, with various immune checkpoint inhibitors showing survival improvements over chemotherapy. Increasingly, some of these checkpoint inhibitors are also showing promise in cancers previously believed to be refractory to immune attack. Despite the dramatic, practice-changing advances that checkpoint inhibitors brought to the management of patients with metastatic melanoma, most patients who develop stage IV melanoma ultimately die of their disease.
The Lancet Oncology , commentaire, 2014